Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer

Digestive Diseases and Sciences

Volumn 59, Issue 5, 2014, Pages 968-975

  Huang, Yu Jing ^a   Frazier, Marsha L ^a   Zhang, Nianxiang ^a   Liu, Qian ^a   Wei, Chongjuan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Pancreatic cancer; Proteomic profiling; Reverse phase protein arrays

Indexed keywords

B RAF KINASE; BETA CATENIN; BIOLOGICAL MARKER; CHECKPOINT KINASE 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GAB2 PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN BCL X; PROTEIN KINASE B; STAT PROTEIN; TRANSCRIPTION FACTOR YAP1; TUBERIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL MATURATION; CELL STRUCTURE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PROCESSING; PROTEOMICS; REVERSE PHASE PROTEIN ARRAY ANALYSIS; VERY ELDERLY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899921080     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2938-9     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012.
3. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25:2607-2615. (Pubitemid 47041235)
4. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6:369-376. (Pubitemid 40753742)
5. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783. (Pubitemid 41095218)
6. Liang JJ, Kimchi ET, Staveley-O'Carroll KF, Tan D. Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int J Clin Exp Pathol. 2009;2:1-10.
7. Misek DE, Patwa TH, Lubman DM, Simeone DM. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw. 2007;5:1034-1041. (Pubitemid 350247711)
8. Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-447.
9. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 2005;41:2213-2236. (Pubitemid 41415597)
10. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355. (Pubitemid 20140602)
11. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267-275. (Pubitemid 37328862)
12. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 1997;18:533-537. (Pubitemid 27174443)
13. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5:993-996. (Pubitemid 44835126)
14. Xiao GG, Recker RR, Deng HW. Recent advances in proteomics and cancer biomarker discovery. Clin Med Oncol. 2008;2:63-72.
15. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004;64:9018-9026. (Pubitemid 39665512)
16. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 2010;70:6704-6714.
17. Object-Oriented Microarray and Proteomic Analysis (OOMPA). Available at: http://bioinformatics.mdanderson.org/main/OOMPA:Overview. Accessed 6 November 2013.
18. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004;20:1453-1454.
19. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142:219-232.
20. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 1996;93:3636-3641. (Pubitemid 26127592)
21. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol. 1993;88:1928-1933. (Pubitemid 23324412)
22. Niedergethmann M, Alves F, Neff JK, et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer. 2007;97:1432-1440. (Pubitemid 350114784)
23. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16:259-266.
24. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
25. Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med. 2011;135:716-727.
26. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988-1004.
27. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem. 1999;274: 21528-21532.
28. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005;24:7482-7492. (Pubitemid 41637988)
29. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1:707-717.
30. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455-7464. (Pubitemid 41637985)
31. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005;8:179-183. (Pubitemid 41317589)
32. Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:2964-2966. (Pubitemid 43837339)
33. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-430. (Pubitemid 44050136)
34. Nishida K. Role of adaptor molecule Gab2 in mast cell-mediated allergy response. Yakugaku Zasshi. 2013;133:413-418.
35. Vaughan TY, Verma S, Bunting KD. Grb2-associated binding (Gab) proteins in hematopoietic and immune cell biology. Am J Blood Res. 2011;1:130-134.
36. Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci. 2003;94:1029-1033. (Pubitemid 38035515)
37. Pan XL, Ren RJ, Wang G, Tang HD, Chen SD. The Gab2 in signal transduction and its potential role in the pathogenesis of Alzheimer's disease. Neurosci Bull. 2010;26:241-246.
38. Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal. 2009;7:22.
39. Holgado-Madruga M, Moscatello DK, Emlet DR, Dieterich R, Wong AJ. Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci USA. 1997;94:12419-12424. (Pubitemid 27492543)
40. Gu H, Maeda H, Moon JJ, et al. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol. 2000;20:7109-7120.
41. Daly RJ, Gu H, Parmar J, et al. The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene. 2002;21:5175-5181.
42. Fleuren ED, O'Toole S, Millar EK, et al. Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer. 2010;127:1486-1492.
43. Horst B, Gruvberger-Saal SK, Hopkins BD, et al. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol. 2009;174:1524-1533.
44. Zatkova A, Schoch C, Speleman F, et al. GAB2 is a novel target of 11q amplification in AML/MDS. Genes Chromosom Cancer. 2006;45:798-807. (Pubitemid 44182438)
45. Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene. 2012;31:2512-2520.
46. Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ. Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology. 2007;39:326-329. (Pubitemid 46897604)
47. Xu XL, Wang X, Chen ZL, et al. Overexpression of Grb2-associated binder 2 in human lung cancer. Int J Biol Sci. 2011;7:496-504.
48. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol. 2009;129:1614-1627.
49. Zeng G, Germinaro M, Micsenyi A, et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 2006;8:279-289.
50. Pasca di Magliano M, Biankin AV, Heiser PW, et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One. 2007;2:e1155.
51. Wang L, Heidt DG, Lee CJ, et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell. 2009;15:207-219.
52. Inoue M, Sawada T, Uchima Y, et al. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep. 2005;14:1445-1451.
53. Beyer BC, Heiss MM, Simon EH, et al. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer. 2006;106:1026-1035.
54. Lindberg P, Larsson A, Nielsen BS. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer. 2006;118:2948-2956.
55. Hundsdorfer B, Zeilhofer HF, Bock KP, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity-clinical relevance and prognostic value. J Craniomaxillofac Surg. 2005;33:191-196. (Pubitemid 40614180)
56. Lara PC, Lloret M, Valenciano A, et al. Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors. Strahlenther Onkol. 2012;188:1139-1145.